Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Recruiting

Phase 2

Phase 3

Atezolizumab with ChemotherapyEvaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05058651

Conditions

Advanced Extrapulmonary Neuroendocrine Carcinoma

Metastatic Extrapulmonary Neuroendocrine Carcinoma

Recurrent Extrapulmonary Neuroendocrine Carcinoma

Unresectable Extrapulmonary Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-31.